Medical Principles and Practice
Original Paper
Time Course from First Symptom to the Treatment of Lung Cancer in the Eastern Black Sea Region of TurkeyÖzlü T.a · Bülbül Y.a · Öztuna F.a · Çan G.bDepartments of aChest Diseases and bPublic Health, Karadeniz Technical University Medical School, Trabzon, Turkey
Dr. Tevfik Özlü KTÜ Tıp Fakültesi Göğüs Hastalıkları Ab. D. TR–61080 Trabzon (Turkey) Tel. +90 462 377 5468, Fax +90 462 325 7031, E-Mail tozlu@meds.ktu.edu.tr |
|
Abstract
Objectives: To determine the delay between the onset and the diagnosis and treatment of patients with lung cancer in two cancer centres in the Eastern Black Sea Region of Turkey. Subjects and Methods: The records of 226 patients (217 males, 9 females) were evaluated retrospectively for the dates noted for the onset of symptoms, first presentation to a physician, histopathological diagnosis and start of treatment. The median time intervals from the appearance of the first symptom to definitive diagnosis and treatment were calculated. Results: The patients presented to their physicians 30 (range 2–365) days after their complaints began. The time that elapsed between admission and histopathological diagnosis and between the diagnosis and initiation of therapy were 8 (range 1–210) and 17.5 days (range 0–206), respectively. The median time span from presentation to treatment was 30 days (range 1–253). There were no significant time interval differences between onset of symptoms and first presentation and the subsequent diagnostic and therapeutic processes for histopathology, stage of the tumour and treatment procedures (p > 0.05). Conclusion: Reasons for the delayed treatment of lung cancer patients were late presentation to the physician and the long time interval between tissue diagnosis and treatment. This delay was mostly associated with a large number of patients and delayed appointments for imaging procedures – the result of organisational problems within the health services of Turkey.
© 2004 S. Karger AG, Basel
Related Articles:
References
-
Kerdpon D, Sriplung H: Factors related to delay in diagnosis of oral squamous cell carcinoma in southern Thailand. Oral Oncol 2001;37:127–131.
External Resources
-
Pereira JR, Ikari FK, Minamoto H, Cassioli JC: Delay factors in the diagnosis of lung cancer: A public health problem (in Portuguese). Rev Paul Med 1991;109:109–112.
External Resources
-
Silva PP, Pereira JR, Ikari FK, Minamoto H: Lung cancer and the delay in the diagnosis: Analysis of 300 cases (in Portuguese). Rev Assoc Med Bras 1992;38:145–149.
-
Lim KH, Liam CK, Wong CMM: Delay in the presentation of lung cancer in Malaysia. Eur Respir J 2000;16(suppl 31):S226.
-
Knorst MM, Fagundes LP, Dienstmann R, Lisboa TC: Lung cancer: Delays in diagnosis and surgical treatment. Eur Respir J 2000;16(suppl 31):S226.
- Dische S, Gibson D, Parmar M, Saunders MI: Time course from first symptom to treatment in patients with non-small cell lung cancer referred for radiotherapy: A report by the CHART Steering Committee. Thorax 1996;51:1262–1265.
- Billing JS, Wells FC: Delays in the diagnosis and surgical treatment of lung cancer. Thorax 1996;51:903–906.
-
Deegan PC, Stevens S, Heath L, Brunskill J, Kinnear WJ, Johnston ID: Waiting times in lung cancer: What is achievable by a multidisciplinary team? Thorax 1996;51(suppl 3):S7.
-
Lopez Encuentra A, Martin de Nicolas JL, Casado Lopez M, de Miguel Poch E, Marron Fernandez C: Delays in the diagnosis and surgical treatment of bronchogenic carcinoma. Cooperative Group on Bronchogenic Carcinoma of SEPAR (GCCB-S) (in Spanish). Arch Bronconeumol 1998;34:123–126.
External Resources
-
Milleron B, Mangiapan G, Terrioux PH, Rosencher L, Guigay J, Mayaud C: Delay in the diagnosis and treatment of lung cancer. Thorax 1997;52:398.
-
The Lung Cancer Working Party of the British Thoracic Society Standards of Care Committee: BTS recommendations to respiratory physicians for organizing the care of patients with lung cancer. Thorax 1998;53(suppl 53):S1–S8.
-
Murphy D: Lung cancer – timeliness of a rapid diagnostic service. Eur Respir J 2000;16(suppl 31):S226.
Article / Publication Details
Accepted: April 10, 2003
Published online: June 10, 2004
Issue release date: July – August
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 3
ISSN: 1011-7571 (Print)
eISSN: 1423-0151 (Online)
For additional information: https://www.karger.com/MPP
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
